Immune Cells and Transcriptional Signatures Revealed Novel Regulators and Predict Clinical Response to Biologic Therapy in Ulcerative Colitis.

Inflammatory Bowel Disease (IBD), which includes Crohn’s Disease (CD) and Ulcerative Colitis (UC), has a heterogeneous pathogenesis underlined by genetic predisposition, intestinal barrier dysfunction, impaired immune response, and microbiota imbalance [1-3]. This proceeds to aberrant immune cells presence and function in the affected tissue, activation of signaling pathways, and expression of regulators that subsequently drive inflammation [2,4-7]. Using publicly available transcriptomes obtained from large number of UC patients from European and the US cohorts [8-16], we identified systemic immune cell landscape, pathways, and transcriptional signatures specific for UC as well as those determining outcome of biologic therapy [17]. immune cell colonic cells, active